<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01916304</url>
  </required_header>
  <id_info>
    <org_study_id>LE-9999-401-BE</org_study_id>
    <secondary_id>2012-005732-28</secondary_id>
    <secondary_id>U1111-1145-3526</secondary_id>
    <nct_id>NCT01916304</nct_id>
  </id_info>
  <brief_title>Study of Dose Adjustment From Levothyroxine to a New Levothyroxine Sodium Test Formulation</brief_title>
  <official_title>A Multicentre, Open-label Switch Study to Investigate the Necessity of Dose Adjustment After Switching From L-Thyroxine Christiaens® to the New Levothyroxine Sodium Test Formulation in (Near) Total Thyroidectomised Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effect of switching participants taking
      levothyroxine to a new sodium formulation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The drug being tested in this study is a new sodium formulation of levothyroxine.
      Levothyroxine (L-Thyroxine Christiaens®) is used in the treatment of hypothyroidism. This
      study will investigate the effect of switching subjects taking levothyroxine to a new
      levothyroxine sodium formulation.

      The results of this study will be used to provide instructions to general practitioners and
      endocrinologists assisting patients on levothyroxine hormone substitution in performing the
      switch to the new formulation.

      The study will enroll approximately 90 patients. Patients receiving the same daily dose of
      L-Thyroxine Christiaens® during the past 6 weeks and with serum thyroid stimulating hormone
      (TSH) levels between 0.4-2.5 mU/L will be switched to the equivalent daily dose of the new
      formulation of levothyroxine. After the switch, patients will be followed up after 2 (± 2
      weeks) and 4 months (± 4 weeks).

      All participants will be asked to take a daily dose at the same time each day throughout the
      study.

      This study will be conducted in Belgium. Participants will make 3 to 4 visits to the clinic.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants That Do Not Need a Change of Dose</measure>
    <time_frame>2 months (± 2 weeks) after switch to sodium formulation.</time_frame>
    <description>Dose change was determined by physician according to their clinical judgement.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Magnitude of the Change in Daily Dose Needed</measure>
    <time_frame>2 months (± 2 weeks) after switch to sodium formulation.</time_frame>
    <description>Magnitude was determined via a change table which provides the percentage of participants that needed a change in Daily Dose (μg/day) of -25 μg, -12.5 μg, -6.25 μg, -5.35 μg, 0 μg or +12.5 μg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants That Obtained a Thyroid Stimulating Hormone (TSH) Between 0.4-2.5 mU/L</measure>
    <time_frame>Month 4 (± 4 weeks) after inclusion into study.</time_frame>
    <description>Blood samples were collected and samples were analyzed according to the local Quality System.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Serum Thyroid Stimulating Hormone Values</measure>
    <time_frame>Baseline, Month 2 (± 2 weeks) and Month 4 (± 4 weeks) after inclusion into study.</time_frame>
    <description>Blood samples were collected and samples were analyzed according to the local Quality System.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative Percent Change From Baseline in Serum Thyroid Stimulating Hormone</measure>
    <time_frame>Baseline, Month 2 (± 2 weeks) and Month 4 (± 4 weeks) after inclusion into study.</time_frame>
    <description>Blood samples were collected and samples were analyzed according to the local Quality System. A negative change from Baseline indicated improvement.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">101</enrollment>
  <condition>Hypothyroidism</condition>
  <arm_group>
    <arm_group_label>Levothyroxine sodium new formulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Levothyroxine (25-225 μg), tablets, orally, once daily for up to 12 to 20 weeks. Dose administered depends on the thyroid stimulating hormone level.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levothyroxine sodium new formulation</intervention_name>
    <description>Levothyroxine tablets</description>
    <arm_group_label>Levothyroxine sodium new formulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. (Near) total thyroidectomised patients.

          2. Aged 18 years and older.

          3. Stabilised on the same daily dose of L-Thyroxine Christiaens® during the last 6 weeks
             before inclusion in the study.

          4. Written informed consent given.

          5. Able and willing to comply with protocol requirements and to complete the study.

        Exclusion Criteria:

          1. History of Graves' disease or positive TSH-receptor antibodies.

          2. History of thyroid cancer requiring TSH suppression.

          3. Medical procedures or treatments planned that could influence the thyroid hormone
             state of the patients during this trial.

          4. Use of levothyroxine containing medicines provided by other brands to treat
             hypothyroidism.

          5. Pregnant or planning pregnancy. Female patients of childbearing potential need to
             apply highly effective methods of birth control.

          6. Participation in another trial in the past 6 weeks.

          7. Exclusion criteria during the study are the occurrence of any serious adverse
             reaction, any laboratory or clinically relevant change in patient status, any change
             in smoking status, use of drugs non-authorized by the physician (to avoid relevant
             drug interactions) and lack of patient compliance with the study drug. (OR events not
             considered as exclusion criteria but to be documented in the case report form, as a
             possible explanation for change in lab parameters and/or dose switch).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Responsible</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 1, 2013</study_first_submitted>
  <study_first_submitted_qc>August 1, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2013</study_first_posted>
  <results_first_submitted>June 22, 2015</results_first_submitted>
  <results_first_submitted_qc>June 22, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 20, 2015</results_first_posted>
  <last_update_submitted>June 22, 2015</last_update_submitted>
  <last_update_submitted_qc>June 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypothyroidism</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in the study at 8 investigative sites in Belgium from 02 July 2013 (first patient screened) to 23 June 2014.</recruitment_details>
      <pre_assignment_details>Participants with a diagnosis of Primary Hypothyroidism were switched from treatment with L-Thyroxine Christiaens® to treatment with new levothyroxine sodium 25-225 μg.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Levothyroxine Sodium New Formulation</title>
          <description>Levothyroxine (25-225 μg), tablets, orally, once daily for up to 12 to 20 weeks. Dose administered depends on the thyroid stimulating hormone level.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="101"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Set</title>
              <participants_list>
                <participants group_id="P1" count="101"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Intent-to-Treat Set</title>
              <participants_list>
                <participants group_id="P1" count="84"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="84"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Screening failure</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Levothyroxine Sodium New Formulation</title>
          <description>Levothyroxine (25-225 μg), tablets, orally, once daily for up to 12 to 20 weeks. Dose administered depends on the thyroid stimulating hormone level.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="101"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.1" spread="12.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <description>Weight data is available for 100 participants.</description>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76.9" spread="18.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <description>Height data was available for 96 participants.</description>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="168.4" spread="8.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Investigator Reported Body Mass Index (BMI)</title>
          <description>Investigator reported BMI data was available for 93 participants.</description>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.2" spread="5.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Calculated BMI</title>
          <description>Calculated BMI data was available for 96 participants.</description>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.1" spread="6.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants That Do Not Need a Change of Dose</title>
        <description>Dose change was determined by physician according to their clinical judgement.</description>
        <time_frame>2 months (± 2 weeks) after switch to sodium formulation.</time_frame>
        <population>Participants from the intent-to-treat population, with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Levothyroxine Sodium New Formulation</title>
            <description>Levothyroxine (25-225 μg), tablets, orally, once daily for up to 12 to 20 weeks. Dose administered depends on the thyroid stimulating hormone level.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants That Do Not Need a Change of Dose</title>
          <description>Dose change was determined by physician according to their clinical judgement.</description>
          <population>Participants from the intent-to-treat population, with data available for analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.9" lower_limit="23.7" upper_limit="43.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Magnitude of the Change in Daily Dose Needed</title>
        <description>Magnitude was determined via a change table which provides the percentage of participants that needed a change in Daily Dose (μg/day) of -25 μg, -12.5 μg, -6.25 μg, -5.35 μg, 0 μg or +12.5 μg.</description>
        <time_frame>2 months (± 2 weeks) after switch to sodium formulation.</time_frame>
        <population>Participants from the intent-to-treat population, with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Levothyroxine Sodium New Formulation</title>
            <description>Levothyroxine (25-225 μg), tablets, orally, once daily for up to 12 to 20 weeks. Dose administered depends on the thyroid stimulating hormone level.</description>
          </group>
        </group_list>
        <measure>
          <title>Magnitude of the Change in Daily Dose Needed</title>
          <description>Magnitude was determined via a change table which provides the percentage of participants that needed a change in Daily Dose (μg/day) of -25 μg, -12.5 μg, -6.25 μg, -5.35 μg, 0 μg or +12.5 μg.</description>
          <population>Participants from the intent-to-treat population, with data available for analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>-25 μg change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>-12.5 μg change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>-6.25 μg change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>-5.35 μg change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0 μg change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>+12.5 μg change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants That Obtained a Thyroid Stimulating Hormone (TSH) Between 0.4-2.5 mU/L</title>
        <description>Blood samples were collected and samples were analyzed according to the local Quality System.</description>
        <time_frame>Month 4 (± 4 weeks) after inclusion into study.</time_frame>
        <population>Participants from the intent-to-treat population, with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Levothyroxine Sodium New Formulation</title>
            <description>Levothyroxine (25-225 μg), tablets, orally, once daily for up to 12 to 20 weeks. Dose administered depends on the thyroid stimulating hormone level.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants That Obtained a Thyroid Stimulating Hormone (TSH) Between 0.4-2.5 mU/L</title>
          <description>Blood samples were collected and samples were analyzed according to the local Quality System.</description>
          <population>Participants from the intent-to-treat population, with data available for analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Serum Thyroid Stimulating Hormone Values</title>
        <description>Blood samples were collected and samples were analyzed according to the local Quality System.</description>
        <time_frame>Baseline, Month 2 (± 2 weeks) and Month 4 (± 4 weeks) after inclusion into study.</time_frame>
        <population>Participants from the intent-to-treat population, with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Levothyroxine Sodium New Formulation</title>
            <description>Levothyroxine (25-225 μg), tablets, orally, once daily for up to 12 to 20 weeks. Dose administered depends on the thyroid stimulating hormone level.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Serum Thyroid Stimulating Hormone Values</title>
          <description>Blood samples were collected and samples were analyzed according to the local Quality System.</description>
          <population>Participants from the intent-to-treat population, with data available for analysis.</population>
          <units>mIU/mL</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="0.59" lower_limit="0.7" upper_limit="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2 (n=83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="1.69" lower_limit="0.1" upper_limit="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 4 (n=82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="1.09" lower_limit="0.2" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relative Percent Change From Baseline in Serum Thyroid Stimulating Hormone</title>
        <description>Blood samples were collected and samples were analyzed according to the local Quality System. A negative change from Baseline indicated improvement.</description>
        <time_frame>Baseline, Month 2 (± 2 weeks) and Month 4 (± 4 weeks) after inclusion into study.</time_frame>
        <population>Participants from the intent-to-treat population, with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Levothyroxine Sodium New Formulation</title>
            <description>Levothyroxine (25-225 μg), tablets, orally, once daily for up to 12 to 20 weeks. Dose administered depends on the thyroid stimulating hormone level.</description>
          </group>
        </group_list>
        <measure>
          <title>Relative Percent Change From Baseline in Serum Thyroid Stimulating Hormone</title>
          <description>Blood samples were collected and samples were analyzed according to the local Quality System. A negative change from Baseline indicated improvement.</description>
          <population>Participants from the intent-to-treat population, with data available for analysis.</population>
          <units>percent change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-74.5" spread="192.14" lower_limit="-89.5" upper_limit="-50.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 4 (n=82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-54.0" spread="173.36" lower_limit="-75.1" upper_limit="-15.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>5 months from inclusion (all patients) or up to recovery/final status is known for AE’s.</time_frame>
      <desc>At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Levothyroxine Sodium New Formulation</title>
          <description>Levothyroxine (25-225 μg), tablets, orally, once daily for up to 12 to 20 weeks. Dose administered depends on the thyroid stimulating hormone level.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Post procedural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Catheterisation cardiac</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Bladder catheterisation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Hysterectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Mastectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Salivary gland resection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director, Clinical Science</name_or_title>
      <organization>Takeda</organization>
      <phone>+1-877-825-3327</phone>
      <email>trialdisclosures@takeda.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

